AAPL   375.51 (+0.44%)
FB   243.93 (+1.52%)
AMZN   3,039.08 (-0.59%)
NVDA   398.47 (+1.25%)
TSLA   1,396.99 (+1.85%)
ACB   12.47 (+2.38%)
GILD   76.66 (-0.13%)
BAC   23.08 (-2.45%)
NFLX   494.21 (+0.08%)
BA   182.14 (-3.07%)
AAPL   375.51 (+0.44%)
FB   243.93 (+1.52%)
AMZN   3,039.08 (-0.59%)
NVDA   398.47 (+1.25%)
TSLA   1,396.99 (+1.85%)
ACB   12.47 (+2.38%)
GILD   76.66 (-0.13%)
BAC   23.08 (-2.45%)
NFLX   494.21 (+0.08%)
BA   182.14 (-3.07%)
AAPL   375.51 (+0.44%)
FB   243.93 (+1.52%)
AMZN   3,039.08 (-0.59%)
NVDA   398.47 (+1.25%)
TSLA   1,396.99 (+1.85%)
ACB   12.47 (+2.38%)
GILD   76.66 (-0.13%)
BAC   23.08 (-2.45%)
NFLX   494.21 (+0.08%)
BA   182.14 (-3.07%)
AAPL   375.51 (+0.44%)
FB   243.93 (+1.52%)
AMZN   3,039.08 (-0.59%)
NVDA   398.47 (+1.25%)
TSLA   1,396.99 (+1.85%)
ACB   12.47 (+2.38%)
GILD   76.66 (-0.13%)
BAC   23.08 (-2.45%)
NFLX   494.21 (+0.08%)
BA   182.14 (-3.07%)
Log in

NASDAQ:OTLKOutlook Therapeutics Stock Price, Forecast & News

$1.31
+0.01 (+0.77 %)
(As of 07/7/2020 02:12 PM ET)
Add
Compare
Today's Range
$1.30
Now: $1.31
$1.37
50-Day Range
$0.72
MA: $1.12
$1.41
52-Week Range
$0.50
Now: $1.31
$2.89
Volume20,845 shs
Average Volume4.00 million shs
Market Capitalization$119.71 million
P/E RatioN/A
Dividend YieldN/A
Beta0.35
Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibody for various ophthalmic indications. Its lead product candidate is ONS-5010, a proprietary ophthalmic bevacizumab product candidate that is in first clinical trial for the treatment of wet age related macular degeneration and other retina diseases. The company has collaboration and license agreements with MTTR, LLC; IPCA Laboratories Limited; Laboratorios Liomont, S.A. de C.V.; BioLexis Pte. Ltd.; and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in December 2018. The company was founded in 2010 and is headquartered in Cranbury, New Jersey.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.37 out of 5 stars


Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:OTLK
CUSIPN/A
CIKN/A
Phone609-619-3990

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$8.15 million
Book Value($0.56) per share

Profitability

Net Income$-34,520,000.00

Miscellaneous

Employees56
Market Cap$119.71 million
Next Earnings Date8/12/2020 (Estimated)
OptionableNot Optionable

Receive OTLK News and Ratings via Email

Sign-up to receive the latest news and ratings for OTLK and its competitors with MarketBeat's FREE daily newsletter.

Outlook Therapeutics (NASDAQ:OTLK) Frequently Asked Questions

How has Outlook Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Outlook Therapeutics' stock was trading at $0.6601 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, OTLK shares have increased by 98.5% and is now trading at $1.31. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Outlook Therapeutics?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Outlook Therapeutics in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Outlook Therapeutics.

When is Outlook Therapeutics' next earnings date?

Outlook Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, August 12th 2020. View our earnings forecast for Outlook Therapeutics.

How were Outlook Therapeutics' earnings last quarter?

Outlook Therapeutics, Inc. (NASDAQ:OTLK) announced its quarterly earnings results on Friday, May, 15th. The company reported ($0.36) earnings per share for the quarter, missing the consensus estimate of ($0.10) by $0.26. View Outlook Therapeutics' earnings history.

When did Outlook Therapeutics' stock split? How did Outlook Therapeutics' stock split work?

Outlook Therapeutics shares reverse split on the morning of Monday, March 18th 2019. The 1-8 reverse split was announced on Friday, March 15th 2019. The number of shares owned by shareholders was adjusted after the market closes on Friday, March 15th 2019. An investor that had 100 shares of Outlook Therapeutics stock prior to the reverse split would have 13 shares after the split.

What price target have analysts set for OTLK?

4 equities research analysts have issued 12 month target prices for Outlook Therapeutics' shares. Their forecasts range from $6.00 to $9.00. On average, they anticipate Outlook Therapeutics' share price to reach $7.33 in the next twelve months. This suggests a possible upside of 459.8% from the stock's current price. View analysts' price targets for Outlook Therapeutics.

Has Outlook Therapeutics been receiving favorable news coverage?

Headlines about OTLK stock have been trending negative recently, according to InfoTrie Sentiment. InfoTrie scores the sentiment of press coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Outlook Therapeutics earned a news impact score of -2.1 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the near term. View the latest news about Outlook Therapeutics.

Are investors shorting Outlook Therapeutics?

Outlook Therapeutics saw a increase in short interest in June. As of June 30th, there was short interest totaling 2,790,000 shares, an increase of 29.8% from the June 15th total of 2,150,000 shares. Based on an average daily trading volume, of 1,760,000 shares, the short-interest ratio is currently 1.6 days. Currently, 14.3% of the company's stock are sold short. View Outlook Therapeutics' Current Options Chain.

Who are some of Outlook Therapeutics' key competitors?

What other stocks do shareholders of Outlook Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Outlook Therapeutics investors own include Matinas BioPharma (MTNB), Amplify Energy (AMPY), Amplify Energy (AMPY), Acasti Pharma (ACST), AzurRx BioPharma (AZRX), Unum Therapeutics (UMRX), SCYNEXIS (SCYX), KushCo (KSHB), Polarityte (PTE) and Miragen Therapeutics (MGEN).

Who are Outlook Therapeutics' key executives?

Outlook Therapeutics' management team includes the following people:
  • Mr. Lawrence A. Kenyon, Pres, CEO, CFO, Company Sec., Treasurer & Director (Age 53)
  • Dr. Pankaj Mohan, Founder & Director (Age 54)
  • Dr. Kenneth M. Bahrt, Chief Medical Officer (Age 66)
  • Mr. Terry Dagnon, Chief Operating Officer (Age 57)
  • Rick Gregory, Director of Marketing & Communications

What is Outlook Therapeutics' stock symbol?

Outlook Therapeutics trades on the NASDAQ under the ticker symbol "OTLK."

How do I buy shares of Outlook Therapeutics?

Shares of OTLK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Outlook Therapeutics' stock price today?

One share of OTLK stock can currently be purchased for approximately $1.31.

How big of a company is Outlook Therapeutics?

Outlook Therapeutics has a market capitalization of $119.71 million and generates $8.15 million in revenue each year. The company earns $-34,520,000.00 in net income (profit) each year or ($1.98) on an earnings per share basis. Outlook Therapeutics employs 56 workers across the globe.

What is Outlook Therapeutics' official website?

The official website for Outlook Therapeutics is www.outlooktherapeutics.com.

How can I contact Outlook Therapeutics?

Outlook Therapeutics' mailing address is 4260 U.S. ROUTE 1, MONMOUTH JUNCTION NJ, 08852. The company can be reached via phone at 609-619-3990 or via email at [email protected]

This page was last updated on 7/7/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.